Evaluation of nicotine pharmacokinetics and subjective effects following use of a novel nicotine delivery system

Nicotine and Tobacco Research

Volumn 20, Issue 4, 2018, Pages 458-465

  Teichert, Axel ^a   Brossard, Patrick ^a   Medlin, Loyse Felber ^a   Sandalic, Larissa ^a   Franzon, Mikael ^a   Wynne, Chris ^b   Laugesen, Murray ^c   Lüdicke, Frank ^a  

^a Philip Morris Products SA   (Switzerland)

^b Christchurch Clinical Studies Trust   (New Zealand)

^c Health New Zealand Ltd   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

LACTIC ACID; NICOTINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CAUCASIAN; CRAVING; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM CONCENTRATION; NORMAL HUMAN; OPEN STUDY; PHARMACODYNAMIC PARAMETERS; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; SCORING SYSTEM; VISUAL ANALOG SCALE CRAVING SCORE; BLOOD; CROSSOVER PROCEDURE; ELECTRONIC CIGARETTE; EVALUATION STUDY; INHALATIONAL DRUG ADMINISTRATION; PROCEDURES; PSYCHOLOGY; QUESTIONNAIRE; SMOKING; SMOKING CESSATION; TRENDS; YOUNG ADULT;

ADMINISTRATION, INHALATION; ADULT; CRAVING; CROSS-OVER STUDIES; ELECTRONIC NICOTINE DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; NICOTINE; SMOKERS; SMOKING CESSATION; SURVEYS AND QUESTIONNAIRES; TOBACCO SMOKING; YOUNG ADULT;

EID: 85043592862     PISSN: 14622203     EISSN: 1469994X     Source Type: Journal    
DOI: 10.1093/ntr/ntx093     Document Type: Article

References (36)

1. Stratton K, Shetty P, Wallace R, Bondurant S. Clearing the smoke: assessing the science base for tobacco harm reduction. Tob Control. 2001;10:189-195.
2. Royal College of Physicians. Harm Reduction in Nicotine Addiction: Helping People Who Can't Quit. A report by the Tobacco Advisory Group of the Royal College of Physicians. London: RCP; 2007.
3. Rose JE, Turner JE, Murugesan T, Behm FM, Laugesen M. Pulmonary delivery of nicotine pyruvate: sensory and pharmacokinetic characteristics. Exp Clin Psychopharmacol. 2010;18(5):385-394. doi:10.1037/ a0020834.
4. Shahab L, Brose LS, West R. Novel delivery systems for nicotine replacement therapy as an aid to smoking cessation and for harm reduction: rationale, and evidence for advantages over existing systems. CNS Drugs. 2013;27(12):1007-1019. doi:10.1007/s40263-013-0116-4.
5. Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 2008;83(4). doi:10.1038/clpt.2008.3.
6. Mc Neill A, Brose LS, Calder R, Hitchman SC, Hajek P. E-cigarettes: an Evidence Update. A Report Commissioned by Public Health England. 2015; Available from: https://www.gov.uk/government/uploads/system/ uploads/attachment_data/file/457102/Ecigarettes_an_evidence: update_A_report_commissioned_by_Public_Health_England_FINAL.pdf (Accessed on 10 June 2016).
7. Kalkhoran S, Glantz SA. E-cigarettes and smoking cessation in real-world and clinical settings: a systematic review and meta-analysis. Lancet Respir Med. 2016;4(2):116-128. doi:10.1016/s2213-2600(15)00521-4.
8. St Helen G, Havel C, Dempsey D, Jacob P, 3rd, Benowitz NL. Nicotine delivery, retention and pharmacokinetics from various electronic cigarettes. Addiction. 2015. doi:10.1111/add.13183.
9. Farsalinos KE, Spyrou A, Stefopoulos C, et al. Nicotine absorption from electronic cigarette use: comparison between experienced consumers (vapers) and naive users (smokers). Sci Rep. 2015;5:11269. doi:10.1038/ srep11269.
10. Khoudigian S, Devji T, Lytvyn L, Campbell K, Hopkins R, O'Reilly D. The efficacy and short-term effects of electronic cigarettes as a method for smoking cessation: a systematic review and a meta-analysis. Int J Public Health. 2016;61(2):257-267. doi:10.1007/s00038-016-0786-z.
11. Farsalinos KE, Spyrou A, Tsimopoulou K, Stefopoulos C, Romagna G, Voudris V. Nicotine absorption from electronic cigarette use: comparison between first and new-generation devices. Sci Rep. 2014;4:4133. doi:10.1038/srep04133.
12. Schneider NG, Olmstead RE, Franzon MA, Lunell E. The nicotine inhaler: clinical pharmacokinetics and comparison with other nicotine treatments. Clin Pharmacokinet. 2001;40(9):661-684.
13. Cipolla DC, Gonda I. Inhaled nicotine replacement therapy. Asian J Pharm Sci. 2015;10(6):472-480. doi:10.1016/j.ajps.2015.07.004.
14. Caldwell B, Sumner W, Crane J. A systematic review of nicotine by inhalation: is there a role for the inhaled route? Nicotine Tob Res. 2012;14(10):1127-1139. doi:10.1093/ntr/nts009.
15. Rose JE, Rose SD, Turner JE, Murugesan T, Inventors; Duke University, Durham, NC (US), assignee. Device and method for delivery of a medicament. US patent 2008/0241255 A1. 2008.
16. Phillips B, Esposito M, Verbeeck J, et al. Toxicity of aerosols of nicotine and pyruvic acid (separate and combined) in Sprague-Dawley rats in a 28-day OECD 412 inhalation study and assessment of systems toxicology. Inhal Toxicol. 2015;27(9):405-431. doi:10.3109/08958378.2015.1046000.
17. Caldwell BO, Crane J. Combination nicotine metered dose inhaler and nicotine patch for smoking cessation: a randomized controlled trial. Nicotine Tob Res. 2016. doi:10.1093/ntr/ntw093.
18. World Medical Association (WMA). WMA Declaration of Helsinki -Ethical Principles for Medical Research Involving Human Subjects. France: WMA; 2013.
19. EMA (European Medicines Agency). Notes for Guidance on Good Clinical Practice (CPMP/ICH/135/95). London: EMA; 1995.
20. New Zealand Medicines, Medical Devices Safety Authority. Guideline on the Regulation of Therapeutic Products in New Zealand; Part 11: Clinical Trials -Regulatory Approval and Good Clinical Practice. Edition 1.4. 2015; Available from: http://www.medsafe.govt.nz/regulatory/currentguidelines. asp (Accessed on 17 July 2016).
21. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm. Stat. 2005;4(4):287-291. doi:10.1002/pst.185.
22. McNeil Products Limited. Nicorette 15mg Inhalator. 2014; Available from: http://www.medicines.org.uk/emc/medicine/24853 (Accessed on 17 June 2016).
23. Health Canada, Tobacco Control Programme. Determination of "Tar," Nicotine and Carbon Monoxide in Mainstream Tobacco Smoke. T-115. Ontario, Canada: Health Canada; 1999.
24. Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO. The Fagerström test for Nicotine Dependence: a revision of the Fagerström Tolerance Questionnaire. Br J Addict. 1991;86(9):1119-1127.
25. Fagerstrom K, Russ C, Yu CR, Yunis C, Foulds J. The Fagerstrom Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data. Nicotine Tob Res. 2012;14(12):1467-1473 doi:10.1093/ntr/nts018.
26. Moyses C, Hearn A, Redfern A. Evaluation of a novel nicotine inhaler device. Part 2: effect on craving and smoking urges. Nicotine Tob Res. 2015;17(1):26-33. doi:10.1093/ntr/ntu122.
27. Cox LS, Tiffany ST, Christen AG. Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings. Nicotine Tob Res. 2001;3:7-16.
28. Cappelleri JC, Bushmakin AG, Baker CL, Merikle E, Olufade AO, Gilbert DG. Confirmatory factor analyses and reliability of the modified cigarette. Addict Behav. 2007;32(5):912-923. doi:10.1016/j.addbeh.2006.06.028.
29. Picavet P, Haziza C, Lama N, Weitkunat R, Lüdicke F. Comparison of the pharmacokinetics of nicotine following single and ad libitum use of a Tobacco Heating System or Combustible Cigarettes. Nicotine Tob Res. 2016;18(5):557-563. doi:10.1093/ntr/ntv220.
30. Kraiczi H, Hansson A, Perfekt R. Single-dose pharmacokinetics of nicotine when given with a novel mouth spray for nicotine replacement therapy. Nicotine Tob Res. 2011;13(12):1176-1182. doi:10.1093/ntr/ntr139.
31. Scherer G, Lee PN. Smoking behaviour and compensation: a review of the literature with meta-analysis. Regul Toxicol Pharmacol. 2014. doi:10.1016/j.yrtph.2014.09.008.
32. Donny EC, Denlinger RL, Tidey JW, et al. Randomized trial of reducednicotine standards for cigarettes. N Engl J Med. 2015;373(14):1340-1349. doi:10.1056/NEJMsa1502403.
33. McKinney DL, Davies BD, Gogova M, et al. Rapid automated blood sampling system for pharmacokinetics studies of cigarette smoking. Nicotine Tob Res. 2010;12(4):319-325. doi:10.1093/ntr/ntp190.
34. Benowitz NL, Hukkanen J, Jacob P, III. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol. 2009(192):29-60. doi:10.1007/978-3-540-69248-5_2.
35. Benowitz NL, Hatsukami D. Gender differences in the pharmacology of nicotine addiction. Addict Biol. 1998;(3):383-404.
36. Caldwell B, Dickson S, Burgess C, et al. A pilot study of nicotine delivery to smokers from a metered-dose inhaler. Nicotine Tob Res. 2009;11(4):342-347. doi:10.1093/ntr/ntp027.